Sandra Grootoonk

Publications (3)2.82 Total impact

• Article: Short-term effects of oral theophylline in addition to CPAP in mild to moderate OSAS.

  Maritta M Orth, Sandra Grootoonk, Hans-Werner Duchna, Justus de Zeeuw, Jörg W Walther, Torsten T Bauer, Gerhard Schultze-Werninghaus, Kurt Rasche
  [show abstract] [hide abstract]
  ABSTRACT: Theophylline is effective in the treatment of central apneas and periodic breathing. In obstructive sleep apnea syndrome (OSAS), results of pharmacological monotherapy with theophylline are inconsistent. The present study investigates whether additional theophylline in patients with OSAS and continuous positive airway pressure (CPAP) therapy might improve ventilation, lower effective CPAP pressure levels or affect sleep architecture. Patients with mild to moderate OSAS (mean apnea index [AI] 12.8+/-11.7) and CPAP therapy (Autoset system; n=16, all male) received either 900 mg of oral sustained-release theophylline (T) or placebo (P) on two separate nights, 3 days apart, using a randomized double-blind crossover study design. There was no change in AI (T: 0.7+/-1.4 vs. P: 0.7+/-0.6/h; P=0.3) or apnea-hypopnea index (AHI; T: 4.3+/-3.3 vs. P: 4.5+/-3.7/h; P=0.84) when theophylline was added to CPAP therapy. We observed no difference in mean CPAP pressure (T: 6.9+/-2.1 vs. P: 6.7+/-1.9 cm H2O; P=0.7) or 95% pressure percentiles (T: 9.7+/-2.7 vs. P: 9.3+/-2.1cm H2O; P=0.3) when nights with theophylline were compared to placebo nights. Theophylline reduced significantly total sleep time (T: 290.6+/-58.9 vs. P: 338.0+/-40.1 min; P=0.02) and thus sleep efficiency (SE; T: 70.5+/-14.9%, P: 82.0+/-70.5%; P=0.005). Rapid eye movement and slow wave sleep were not affected. Oral theophylline did not show any additional effects on ventilation parameters or pressures in patients with mild to moderate OSAS once CPAP therapy has been successfully installed. SE was reduced with theophylline with unchanged sleep architecture. The role of oral theophylline may be in patients with predominately central apneas not eligible for ventilation therapy or severe cases.
  Respiratory Medicine 05/2005; 99(4):471-6. · 2.47 Impact Factor
• Article: [Self-Management of Anti-Obstructive Therapy for Severe COPD with a Subcutaneous Terbutaline Pump].

  Sandra Grootoonk, Gerhard Schultze-Werninghaus, Marianne Ehren, Justus De Zeeuw, Hans-Werner Duchna, Torsten Thomas Bauer
  [show abstract] [hide abstract]
  ABSTRACT: Patients with chronic obstructive pulmonary disease (COPD) may be difficult to stabilize with standard inhaled and oral medication. In those cases, outpatient care may even be impossible. Alternative therapeutic strategies, like subcutaneous self-application of terbutaline, could help to further improve health status. A 42-year old patient with severe COPD was admitted to the hospital. Despite maximal anti-obstructive therapy he required additional intravenous relief therapy and discharge was not possible. We treated this patient with a subcutaneous terbutaline pump for continuous and demand medication. We could show a significant decrease in additional intravenous medication, and the patient could leave the hospital. The use of terbutaline applied by a subcutaneous pump in addition to standard therapy may be helpful in severely ill patients suffering from COPD. This measure increased quality of life and shortened hospital stay.
  Medizinische Klinik 11/2003; 98(10):579-82. · 0.34 Impact Factor
• Article: Einsatz eines subkutanen Terbutalin-Infusatsystems zur Selbstapplikation der Bedarfsmedikation bei schwerer chronisch-obstruktiver Atemwegserkrankung (COPD)

  Sandra Grootoonk, Gerhard Schultze-Werninghaus, Marianne Ehren, Justus Zeeuw, Hans-Werner Duchna, TorstenThomas Bauer
  [show abstract] [hide abstract]
  ABSTRACT: Hintergrund: Trotz Ausschpfung konservativer Therapieschemata erreichen einige Patienten mit chronisch-obstruktiver Atemwegserkrankung (COPD) keinen stabilen Zustand, der eine dauerhafte ambulante Therapie zulsst. Alternative Verfahren, wie die Mglichkeit der kontinuierlichen subkutanen Gabe eines 2-Sympathomimetikums ber ein Pumpensystem, knnten neue Wege erffnen. Fallbeschreibung: Geschildert wird der Fall eines 42-jhrigen Patienten, dessen schwerstgradige COPD durch den Einsatz eines Terbutalin-Infusatsystems positiv beeinflusst werden konnte. Schlussfolgerung: Die Verwendung eines Terbutalin-Infusatsystems bei therapierefraktren COPD-Patienten kann zur Stabilisierung des Gesundheitszustands und Verbesserung der Lebensqualitt des Patienten fhren. Background: Patients with chronic obstructive pulmonary disease (COPD) may be difficult to stabilize with standard inhaled and oral medication. In those cases, outpatient care may even be impossible. Alternative therapeutic strategies, like subcutaneous self-application of terbutaline, could help to further improve health status. Case report: A 42-year old patient with severe COPD was admitted to the hospital. Despite maximal anti-obstructive therapy he required additional intravenous relief therapy and discharge was not possible. We treated this patient with a subcutaneous terbutaline pump for continuous and demand medication. We could show a significant decrease in additional intravenous medication, and the patient could leave the hospital.Conclusion:The use of terbutaline applied by a subcutaneous pump in addition to standard therapy may be helpful in severely ill patients suffering from COPD. This measure increased quality of life and shortened hospital stay.
  09/2003; 98(10):579-582.